Xencor Inc
NASDAQ:XNCR
Intrinsic Value
Xencor, Inc. is biopharmaceutical company, which engages in the development of engineered monoclonal antibody therapeutics to treat severe and life-threatening diseases. [ Read More ]
The intrinsic value of one XNCR stock under the Base Case scenario is 34.02 USD. Compared to the current market price of 21.13 USD, Xencor Inc is Undervalued by 38%.
Valuation Backtest
Xencor Inc
Run backtest to discover the historical profit from buying and selling XNCR stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Xencor Inc
Current Assets | 562.3m |
Cash & Short-Term Investments | 535.9m |
Receivables | 9.6m |
Other Current Assets | 16.7m |
Non-Current Assets | 322m |
Long-Term Investments | 198.5m |
PP&E | 103.8m |
Intangibles | 18.9m |
Other Non-Current Assets | 880k |
Current Liabilities | 79.4m |
Accounts Payable | 16m |
Accrued Liabilities | 15.6m |
Other Current Liabilities | 47.8m |
Non-Current Liabilities | 192.3m |
Long-Term Debt | 12.5m |
Other Non-Current Liabilities | 179.8m |
Earnings Waterfall
Xencor Inc
Revenue
|
162.2m
USD
|
Operating Expenses
|
-299.4m
USD
|
Operating Income
|
-137.2m
USD
|
Other Expenses
|
3.7m
USD
|
Net Income
|
-133.4m
USD
|
Free Cash Flow Analysis
Xencor Inc
XNCR Profitability Score
Profitability Due Diligence
Xencor Inc's profitability score is 28/100. The higher the profitability score, the more profitable the company is.
Score
Xencor Inc's profitability score is 28/100. The higher the profitability score, the more profitable the company is.
XNCR Solvency Score
Solvency Due Diligence
Xencor Inc's solvency score is 73/100. The higher the solvency score, the more solvent the company is.
Score
Xencor Inc's solvency score is 73/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
XNCR Price Targets Summary
Xencor Inc
According to Wall Street analysts, the average 1-year price target for XNCR is 37.31 USD with a low forecast of 22.22 USD and a high forecast of 61.95 USD.
Ownership
XNCR Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
XNCR Price
Xencor Inc
Average Annual Return | -4.28% |
Standard Deviation of Annual Returns | 25.51% |
Max Drawdown | -69% |
Market Capitalization | 1.3B USD |
Shares Outstanding | 61 647 500 |
Percentage of Shares Shorted | 19.53% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Xencor, Inc. is biopharmaceutical company, which engages in the development of engineered monoclonal antibody therapeutics to treat severe and life-threatening diseases. The company is headquartered in Monrovia California, California and currently employs 254 full-time employees. The company went IPO on 2013-12-03. The firm is advancing a portfolio of clinical-stage XmAb drug candidates from its protein engineering technology platforms. The firm uses its engineering capabilities to enable its understanding of protein structure and interactions to design technologies and XmAb development candidates with properties. The company is focused on the Fc domain, which is the part of an antibody that interacts with various segments of the immune system and controls antibody structure. The Fc domain is constant and interchangeable among antibodies, and its engineered Fc domains are the XmAb technology, which can be readily substituted for natural Fc domains. Its drug candidates include Plamotamab, XmAb717, Tidutamab, XmAb841, XmAb306, AMG 509, XmAb819, XmAb104, XmAb564 and Novartis XmAb.
Contact
IPO
Employees
Officers
The intrinsic value of one XNCR stock under the Base Case scenario is 34.02 USD.
Compared to the current market price of 21.13 USD, Xencor Inc is Undervalued by 38%.